


### Lyvispah/Fleqsuvy/oral baclofen solution

Oral baclofen solution, Fleqsuvy (baclofen suspension) and Lyvispah granules may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia. In addition, Fleqsuvy and Lyvispah may only be authorized if there is a documented intolerance to oral baclofen solution.

MUSCULOSKELETAL RELAXANT AGENTS USED FOR SPASTICITY				
baclofen tizanidine tablets	baclofen solution* DANTRIUM (dantrolene) dantrolene FLEQSUVY (baclofen)* LYVISPAH GRANULE PACKET (baclofen)* tizanidine capsules ZANAFLEX (tizanidine)	Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.  *Oral baclofen solution, Fleqsuvy (baclofen suspension) and Lyvispah granules may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia. In addition, Fleqsuvy and Lyvispah may only be authorized if there is a documented intolerance to oral baclofen solution.		



### **Myfembree**

**Myfembree** is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and management of moderate to severe pain associated with endometriosis.

#### **CRITERIA FOR APPROVAL:**


- 1. Patient must be a premenopausal woman diagnosed with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or diagnosed with moderate to severe pain associated with endometriosis; AND
- 2. Patient must be within the age range as recommended by the FDA label; AND
- 3. Patient must not be pregnant; AND
- 4. Patient must not be diagnosed with osteoporosis; AND
- 5. For heavy menstrual bleeding associate with uterine leiomyomas (fibroids): The patient has failed a 90-day trial with one agent from **ONE** the following categories (unless contraindicated):
  - a. Combination Estrogen/Progestin contraceptives
  - b. Progestin therapy (oral, transdermal, vaginal ring, IUD, or injections)
  - c. Tranexamic acid
- 6. For moderate to severe pain associated with endometriosis:
  - a. The patient has failed to achieve significant symptomatic relief with NSAID therapy (please provide documentation); **AND**
  - b. Patient has failed a 90-day trial with one agent from ONE of the following categories (unless contraindicated):
    - 1. Extended-cycle combined oral contraceptive OR progestin therapy
    - 2. GnRH agonist

**Approval Duration**: Initial approval will be for 90 days.

#### Criteria for reauthorization:


- 1. Demonstrate continued documented compliance; AND
- 2. Patient has experienced clinically significant improvement in symptoms as compared to that seen using previous therapy.

<u>Maximum length of therapy is limited to 24 months due to the risk of continued bone loss, which</u> may not be reversible.



### <u>Orilissa/Oriahnn</u>

\*Full PA criteria for Myfembree, Orilissa and Oriahnn may be found on the <u>PA Criteria</u> page by clicking the hyperlink. In addition, Orilissa and Oriahnn may only be approved if there is a documented side effect, allergy, or treatment failure with Myfembree. Use of GnRH receptor antagonists will be limited to 24 months.



CLASS PA CRITERIA: Unless otherwise noted, non-preferred agents are available only on appeal

FENSOLVI SYRINGE (leuprolide acetate)
LUPANETA (leuprolide)
LUPRON DEPOT KIT (leuprolide)
LUPRON DEPOT-PED KIT (leuprolide)
MYFEMBREE (relugolix, estradiol,
norethindrone)\*

leuprolide
ORIAHNN (elagolix-estradiol-norethindrone)\*
ORILISSA (elagolix)\*
SUPPRELIN LA KIT (histrelin)

\* Full PA criteria may be found on the <u>PA Criteria</u> page by clicking the hyperlink.

\*Full PA criteria for Myfembree, Orilissa and Oriahnn may be found on the <u>PA Criteria</u> page by clicking the hyperlink. In addition, Orilissa and Oriahnn may only be approved if there is

A4




# BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE 01/01/2023 Version 2023.1A

SYNAREL (nafarelin) TRELSTAR (triptorelin) TRIPTODUR (triptorelin) ZOLADEX (goserelin) a documented side effect, allergy, or treatment failure with Mytembree. Use of GnRH receptor antagonists will be limited to 24 months.



### <u>Fintepla</u>

**Fintepla** is indicated for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients 2 years of age and older

#### **CRITERIA FOR APPROVAL:**

- The patient has a diagnosis of Dravet Syndrome or Lennox-Gastaut syndrome;
   AND
- The patient must be within the age range as recommended by the FDA label and indication; AND
- 3. Fintepla is prescribed by, or in consultation with a neurologist; AND
- 4. The prescriber, pharmacy, and patient must all be enrolled in the FINTEPLA REMS program; **AND**
- Documentation of current baseline seizure activity per month must be provided;AND
- 6. For Dravet Syndrome: The patient must have treatment failure/inadequate response to valproate and clobazam. If there is an intolerance, allergy, or contraindication to valproate, one other preferred antiepileptic (such as topiramate or levetiracetam) must be trialed; AND
- 7. For Lennox-Gastaut syndrome: The patient must have treatment failure/inadequate response or intolerance to valproate, lamotrigine and Clobazam, unless contraindicated
- 8. Evaluation with echocardiography for valvular disease and pulmonary hypertension is required before treatment, every six months during treatment, and once three to six months after treatment. to monitor for valvular heart disease and pulmonary hypertension.
- 9. Will not be approved if prescribed as monotherapy for LGS or Dravet.

### **Approval Duration:**


Initial approval will be for 6 months.

Criteria for reauthorization:



- 1. Patient must continue to meet initial approval criteria; AND
- 2. Demonstrate continued documented compliance; AND
- 3. Documented decrease from baseline in seizure frequency per month must be provided.

Continuation of therapy approvals will be granted for 12 months.



### <u>Dupixent</u>

**DUPIXENT** is an interleukin-4 receptor alpha antagonist indicated:

#### **Atopic Dermatitis**

for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

#### <u>Asthma</u>

as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus.

#### Chronic Rhinosinusitis with Nasal Polyposis

as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

### Eosinophilic Esophagitis

for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).


#### **Prurigo Nodularis**

for the treatment of adult patients with prurigo nodularis (PN).

For the indication of Eosinophilic Esophagitis, prior authorization requests may be approved if the following criteria are met:

- Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or gastroenterologist; AND
- 2. The patient must be within the age range as recommended by the FDA label and indication; AND
- The patient has an eosinophilic count ≥15 eosinophils per high-power microscopy field (eos/hpf);
   AND
- 4. The patient has symptoms of dysphagia or prior history of esophageal dilation; AND
- 5. The patient has had a 90-day trial resulting in an inadequate response to topical/systemic glucocorticoids, unless contraindicated.

Initial approval of Dupixent for Eosinophilic Esophagitis will be for 90 days. Additional therapy shall be approvable with documentation showing that the member has achieved a significant reduction in dysphagia symptoms since treatment initiation. and has an esophageal intraepithelial eosinophil count of ≤6 eos/hp.



For the indication of Prurigo Nodularis, prior authorization requests may be approved if the following criteria are met:

- 1. Prescribed by or in consultation with a dermatologist, allergist, or immunologist; AND
- 2. The patient must be within the age range as recommended by the FDA label and indication; AND
- 3. Patient has a Worst Itch Numeric Rating Scale (WI-NRS) score of ≥7 on a scale of 0 to 10; AND
- 4. The patient has at least 20 nodular lesions; AND
- 5. The patient has had a trial resulting in an inadequate response/treatment failure to a super potent topical corticosteroid or an intralesional corticosteroid, unless contraindicated.

Initial approval of Dupixent for Prurigo Nodularis will be for 90 days. Additional therapy shall be approvable with documentation of satisfactory patient response and compliance on therapy.

### **Kesimpta**

Kesimpta may be approved with documentation of treatment failure/inadequate treatment response after a 90-day trial of at least one preferred MS agent. Member must have a negative Hepatitis-B test, please provide documentation.

#### MULTIPLE SCLEROSIS AGENTSCL

CLASS PA CRITERIA: All agents require a prior authorization and documented diagnosis of multiple sclerosis. Preferred oral agents require a ninety (90) day trial of any preferred injectable agent. Non-preferred agents require ninety (90) day trials of two (2) chemically unique preferred agents (in the same sub-class) before they will be approved, unless one (1) of the exceptions on the PA form is present.

AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a) INTERFERONS<sup>AP</sup>
EXTAVIA KIT (interferon beta-1b)
EXTAVIA VIAL (interferon beta-1b) PLEGRIDY (peginterferon beta-1a)

NON-INTERFERONS

AUBAGIO (teriflunomide)<sup>4</sup> COPAXONE 20 mg (glatiramer) dalfampridine ER\*\* GILENYA (fingolimod)

KESIMPTÀ INJECTION (ofatumumab)

AMPYRA (dalfampridine)\*\*
BAFIERTAM CAPSULES (monomethyl fumarate) COPAXONE 40 mg (glatiramer)\* glatiramer GLATOPA (glatiramer) MAVENCLAD (cladribine)

PONVORY (ponesimod)

sulfate)
TECFIDERA (dimethyl
VUMERITY (diroximel) thyl <u>fumarate)\*</u>\*\* ZEPOSIA (ozanimod)

MAYZENT (siponimod)

In addition to class PA criteria, the following conditions and criteria may also apply:

\*Aubagio requires the following additional criteria to be met:

- Diagnosis of relapsing multiple sclerosis and
- Measurement of transaminase and bilirubin levels within the (6) months before initiation of therapy and ALT levels at least monthly for six (6) months after
- initiation of therapy **and**Complete blood cell count (CBC) within six (6) months before initiation of therapy **and**
- Female patients must have a negative pregnancy test before initiation of therapy and be established on a reliable method of contraception if appropriate **and**
- Patient is between eighteen (18) up to sixty-five (65) years of age **and**Negative tuberculin skin test before initiation of
- therapy




#### **BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID** PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE** 01/01/2023 Version 2023.1A

**Dalfampridine ER and Ampyra require the following additional criteria to be met:  1. Diagnosis of multiple sclerosis and 2. No history of seizures and 3. No evidence of moderate or severe renal impairment.  ***Dimethyl fumerate and Tecfidera require the following additional criteria to be met: 1. Diagnosis of relapsing multiple sclerosis and 2. Complete blood count (CBC) within six (6) months of initiation of therapy and six (6) months after initiation and 3. Complete blood count (CBC) annually during therapy.  ****Copaxone 40mg will only be authorized for documented injection site issues.  *******Mayzent may be authorized with no additional requirement beyond the diagnosis for patients with documented secondary progressive MS.  Kesimpta may be approved with documentation of treatment failure/inadequate treatment response after a 90-day trial of at least one preferred MS agent.



## <u>Belsomra</u>

\*Belsomra may be approved after a trial of zolpidem and or temazepam, unless one of the exceptions on the PA form is present.

SEDATIVE HYPNOTICSAP

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of all preferred agents in BOTH sub-classes before they will be approved, unless one (1)

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of all preferred agents in BOTH sub-classes before they will be approved, unless one (1)

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of all preferred agents in BOTH sub-classes before they will be approved, unless one (1)

	agents <u>except melatonin</u> will be limited to fifteen (15) rithout a PA. Melatonin labeler code 51645 is preferre	tablets in a thirty (30) day period. NOTE: WV Medicaid covers of if available, however all NDCs are payable.		
BENZODIAZEPINES				
temazepam 15, 30 mg	estazolam flurazepam HALCION (triazolam) QUVIVIQ (daridorexant) RESTORIL (temazepam) temazepam 7.5, 22.5 mg triazolam			
	OTHERS			
BELSOMRA (suvorexant)** melatonin ROZEREM (ramelteon) zolpidem 5, 10 mg	AMBIEN (zolpidem) AMBIEN CR (zolpidem) DAYVIGO (lemborexant) doxepin 3mg and 6mg EDLUAR (zolpidem) eszopiclone HETLIOZ (tasimelteon) <sup>CL*</sup> LUNESTA (eszopiclone) ramelteon SILENOR (doxepin) zaleplon zolpidem ER 6.25, 12.5 mg	For treatment naïve female patients, zolpidem and zolpidem ER maximum dosages will be limited to 5 mg and 6.25 mg respectively per day.  *Full PA criteria may be found on the PA Criteria page by clicking the hyperlink.  **Belsomra may be approved after a trial of zolpidem and temazepam, unless one of the exceptions on the PA form is present.		

### Irritable bowel syndrome agents

All agents in this subclass require documentation of the current diagnosis. and evidence that the patient has failed to find relief with dietary modification and a fourteen (14) day trial of an osmotic laxative.

#### IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME/SELECTED GI AGENTS CL

CLASS PA CRITERIA: All agents are approvable only for patients age eighteen (18) and older. See below for additional sub-class criteria.

#### CONSTIPATION

AMITIZA (lubiprostone) LINZESS 145 and 290 mcg (linaclotide) MOVANTIK (naloxegol) TRULANCE (plecanatide) IBSRELA (tenapanor)
LINZESS 72 mcg (linaclotide)
lubiprostone capsule
MOTEGRITY (prucalopride)
RELISTOR INJECTION (methylnaltrexone)
RELISTOR TABLET (methylnaltrexone)
SYMPROIC (naldemedine)

All agents in this subclass require documentation of the current diagnosis, and evidence that the patient has failed to find relief with dietary modification and a fourteen (14) day trial of an esmotic laxative.

Α4



### BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA
This is not an all-inclusive list of available covered drugs and includes only

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL

EFFECTIVE 01/01/2023 Version 2023.1A

managed dategories. Itelef to bover page for bomplete fist of	raics governing and r De.	
	No agent shall be approved to treat opioid induced	
	constipation (OIC) without evidence of at least 90-days of	
	opioid use preceding the request. Continuation of coverage	
	shall be granted with evidence of continuous and concurrent	
	opioid use.	
	opioid use.	
	Agents may be authorized only for their FDA-approved	
	labeled indication. The following agent-specific criteria	
	shall also apply, unless one (1) of the exceptions on the	
	PA form is present:	
	Ibsrela requires thirty (30) day trials of each preferred agent	
	for IBS-C, however for males, a trial of Amitiza is not	
	required.	
	<u>Linzess 72mcg</u> may only be approved for a diagnosis of	
	chronic idiopathic constipation (CIC) AND for those who	
	cannot tolerate the 145mcg dose.	
	Lubiprostone may only be authorized with a	
	documented allergy or intolerance to Amitiza.	
	Motegrity requires a 30-day trial of both Amitiza and Linzess	i.
	Relistor and Symproic are indicated for OIC and require	
	thirty (30) day trials of both Movantik and Amitiza.	
	Trulance requires thirty (30) day trials of both Amitiza and	
	Linzess, however for the indication of IBS-C in males, a trial	
	of Amitiza is not required.	
	Zelnorm is indicated for females < 65 years of age	
	diagnosed with irritable bowel syndrome with constipation	
	(IBS-C) AND requires thirty (30) day trials of Amitiza and	
	Linzess.	